Pneumocystis jiroveci pneumonia (PJP) is a feared opprtunistic infection in the renal transplant population. The unicellular fungus is ubiquitous in the environment but has an untreated mortality of 90–100% in immunocompromised HIV-negative patients [1]. This falls to 35% with treatment [2]. Many, but not all, transplant centres routinely prescribe PJP prophylaxis. Current European Best Practic...